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Background: Antiviral therapy using nucleos(t)ide analogues (NAs) is an effective control measure of chronic
hepatitis B virus (HBV) infection; however they need long term treatment. Presence of drug-resistance mutations
may get in the way of the efficacy of antiviral therapy. Our study was aimed at defining the prevalence of HBV
drug-resistance in HBVrt region in a population of 147 HBsAg positive patients.
Findings: HBV/D has shown multiple types of HBVrt mutations both among treatment naïve (65.0%, 13 of 20 HBV/D)
and treated patients (56.2%, 9 of 16 HBV/D). In additional, several mutations, with a suggested role in drug resistance,
were detected among the treatment naïve as well as the treated patients. The mutations reported to be involved in
reduction of drug effectiveness, was common among non-responders to therapy as well as among the naïve patients.
Notably, classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-
rtS202C /G/I -rtM204V/I-rtN236T-rtM250V) were not detected.
Conclusion: The prevalence of putative NAr mutations among non responders to therapy suggests that they might
have role in reduced efficacy of currently available antivirals and requires further investigations.
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Chronic hepatitis B virus (HBV) infection remains a ser-
ious public health problem in India. Antiviral therapy
using nucleos(t)ide analogues (NAs) is an effective con-
trol measure; however they need long term treatment.
The limited numbers of NAs available and development
of drug resistance conferred by viral mutations in the
HBV reverse transcriptase (rt) domain during long term
treatment remains the major concern leading to treat-
ment failure [1]. Recent reports showed presence of anti-
viral resistance even in HBV isolates from therapy naive
patients [2-4].
Mutations reported in response to available NA therapy
for HBV is defined as primary mutations, which reduces
HBV replication fitness [5]. Secondary/compensatory
mutations develop subsequently that restore the replication
capability of HBV [6]. Genotype-dependent polymorphic* Correspondence: runugc@gmail.com
1ICMR Virus Unit, Kolkata, ID & BG Hospital Campus, Kolkata, India
Full list of author information is available at the end of the article
© 2013 Panigrahi et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the oramino acid (aa) positions were recognized in the HBVrt
that may influence the development of drug resistance.
Recently, HBVrt domain mutations which have been
reported in the literature as supposed drug resistant
mutations but are not verified experimentally were classi-
fied as putative NA resistant (NAr) mutations (such as
S53N, T54N, L82M, V84M, S85A, I91L, Y126C, T128I,
T128N, N139D, W153Q, F166L) [7]. Thus, the HBVrt do-
main mutations can be classified into four categories (pri-
mary drug resistance mutation, secondary/compensatory
mutation, putative NAr mutation and pretreatment muta-
tions). Pretreatment mutations (such as T38A, Y124H,
D134E, N139K/H, I224V, and R242A) were defined as
amino acid substitutions that have been reported among
NA-naive patients but their relationships with antiviral
resistance development have not been clarified yet.
Eight HBV genotypes (A–H) and several subgenotypes
within certain HBV genotypes have been identified [8],
with distinct geographical distributions. Eastern India is
a unique region where three different HBV genotypes
(A, C and D) co circulate among the same ethnic group.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients is still poorly defined. In this cross sectional study,
our focus was to analyze the prevalence of HBV/rt region
mutations in patients from Eastern India.
Materials and methods
Blood samples obtained from 147 HBV surface antigen
(HBsAg) positive patients referred to our unit were
included in this retrospective study. The inclusion cri-
teria were hepatitis B surface antigen (HBsAg) positive;
exclusion criteria were hepatitis C virus or human im-
munodeficiency virus co-infection. Among them HBVrt
region could be successfully amplified and sequenced
from 85 samples (55 antiviral therapy naïve patients
and 30 non-responder to NA therapy). The low amplifi-
cation of the samples may be due to the low copy num-
ber of HBV DNA in the plasma. The treatment drug
selection was lamivudine and combinational therapy
(adefovir and lamivudine). The serology of the patients
was done as described previously [9]. The selection of
non-responder patients were on the basis of the failure
to achieve more than 1 log10 decrease from base-line
within 6 months of starting therapy [10]. The study was
part of a project, approved by the Institutional Ethics
Committee NICED (ICMR) and informed written con-
sent was obtained from all the subjects and was funded
by CSIR, New Delhi.
Nested polymerase chain reaction was used to amplify
HBV RT region using primers (HB1F-50-AAGCTCTGCT
AGATCCCAGAGT-30 (sense 18 to 40); HB6R 50-AACAG
ACCAATTTATGCCTA-30 (antisense 1809 to 1790) in
30 μl reaction volume and 4 μl from the first round product
was amplified using primers B2 50- GGCTCACAGTTCA
CGGAACAGT-30(sense 65 to 86) and HS4R 50- CATACT
TTCCAATCAATAGG-30(antisense 992 to 973) and a
standard thermal cycling profile, with annealing 55°C for
45 s, 45 cycles (40 cycles for the second round).
The amplicons were subjected to direct sequencing
and the data were analyzed as previously described [9].
HBV genotypes were assigned using NCBI Viral Geno-
typing Tool (www.ncbi.nlm.nih.gov/projects/genotyping/
formpage.cgi) and phylogenetic analysis with MEGA 4.0




ALT level [U/L]# 87.7±
Genotype (A/C/D) 22/13
Pol Gene Amplified 55
HBV-DNA (log10 copies/ml)# 5.07±
# Mean ± SD (standard deviation).done as described previously from our laboratory [11].
For statistical calculations, StatCalc (EpiInfo, v 6.0, CDC,
USA program is used. For the purpose of our study, a
‘p’ value less than or equal to 0.05 was considered
statistically significant. Gene Bank Accession numbers:
JQ316695-JQ316779.
Result
Among the 85 DNA positive subjects whose HBV RT
sequences were determined, 70 (82.4%) were male. Of
the treated patients the 12/30 was found to be HBeAg
positive as compared to 28/55 HBeAg positive among
the naive patients. Prevalent HBV genotypes were similar
to that previously reported from eastern India. The main
characteristics of the treated and naïve patients were
compared in Table 1.
Whole genome sequences of a particular genotype
retrieved from GenBank were used to produce a consen-
sus sequence of the whole polymerase gene and were
aligned with the study samples and different mutations
and substitutions were analyzed. Three HBV genotypes
were found, with a prevalence of HBV/A (26/85; 30.5%),
HBV/C (23/85; 27.0%) and HBV/D (36/85; 42.3%).
Compared to HBV/A and HBV/C genotypes, HBV/D
has shown multiple different types of HBVrt mutation
patterns (Putative NAr mutation and Pretreatment mu-
tation) both among naïve and treated patients as 65.0%
(13/20) and 56.2% (9/16) respectively (Table 2). The dif-
ference in the prevalence of HBVrt mutation patterns
among the naïve and treated patients was insignificant
(p=0.9; 34.5% and 36.67% respectively).
HBV RT region consists of 6 functional domains (F, A,
B, C, D and E) and 5 interdomains (F–A, A–B, B–C, C–D
and D–E) [12,13]. Analysis of the domains from naïve
patients revealed the presence of 16 different mutations,
whereas domain C was conserved (Figure 1). When the
interdomains were analyzed a total of 18 mutations
were found including a conserved D-E interdomain. In
addition, the A–B interdomain displayed the most abun-
dant mutations indicating these positions might be natur-
ally occurring mutation hotspots. The known lamivudine
(LMV) resistant mutation rtI187L was found in two ther-







Table 2 Distributation of HBVrt mutations among the three genotypes
Antiviral treated (N= 30) Treatment naïve (N= 55)












I91L (15), Y126H (11)
Y126R (5), W153R (16),










I91L (20), Y126R (13), Y126H (7),
T128I (1), W153R (20), Q215H (1),












Y124H (19), Y124N(1), D134E(1),
I224V(20)
Values in the parentheses indicates number of isolates.
Figure 1 Genotype associated and independent amino acid mutations in the HBVrt domain among the antiviral drug treated and
naïve patients. The four domains of the HBVrt region are indicated by horizontal bars (above). The amino acid alignment of the domain among
the antiviral drug treated and treatment naïve patients are shown and the genotype of each isolate are indicated in the right side.
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rtI91L and rtV103I was found among the HBV/A and
HBV/D but not in HBV/C. All the isolates having rtI91L
were associated with rtV103I. Notably, mutations, re-
cently proposed as NAr mutations i.e. which are poten-
tially associated in reduction of drug effectiveness, were
found in the naïve patients.
Among the treated patients no primary antiviral drug
resistant mutations, confirmed by in vitro studies as
associated with resistance to NA (rtL80I/V-rtI169T-
rtV173LrtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-
rtS202C/G/I-rtM204V/I-rtN236T-rtM250V) were found.
The prevalence of rtI91L was 80% (24/30) among them.
Several other pretreatment mutations were also found in
the treated patients (Figure 1). Two stop codon mutations
were identified at position rtS106* and rtY111* in HBV/D
genotype and both was found to be present as unique
viral variant.
Discussion
In this study several genotype-dependent aa polymorphic
positions were identified for HBV/A, HBV/C and HBV/D
genotypes (Table 2). Our study showed that rtI91L was
favored in HBV/C and HBV/D. This mutation have been
reported to be more common among cases with extended
treatment failure than rtI91, and suggested as potential
pretreatment markers to predict the long term response to
LMV therapy [7]. In addition, Y126H was more frequent
among treatment non responders infected with HBV/D
(68.75%, 11/16) than among treatment naïve patients
infected with HBV/D (35%, 7/20; Table 2), although not
statistically significant (p=0.2). Whereas, in patients infected
with HBV/C or HBV/A, Y126H is common among both
naïve and treated patients. The potential role of HBV
genotypes on modulating resistance development is still
disputed [14]. A recent study by Svicher et al. (2009) [14]
has demonstrated that genotypes A and D had different
preferences for two distinct LMV-resistance mutation
clusters, underscoring possible roles of HBV genotypes in
driving RT sequence evolution under NA treatment. The
present study also shows a high HBVrt polymorphism with
potential role in NA resistance, seen in treatment naïve
patients with HBV/D. This is clinically significant in India,
with a higher burden of chronically infected individuals
with predominance of HBV/D and extensive use of LMV
[15]. Recent study from Spain [16] showed a lower preva-
lence of HBVrt mutations among the HBV/D. This is in
contrast to a higher prevalence of HBVrt mutations, found
in our study. Notably, they have studied mainly well-known
primary NA resistant mutations and a few potential drug
resistant mutations. In contrast our study, analyzed all 4
types of the possible NAr mutations. Additionally, this
might also be due to altered mutational profile because of
HBV/D subgenotype variations between the two geographicregions; as discussed earlier [17]. Therefore, in regions
where more than one genotype/subgenotype is prevalent,
genotype/subgenotype associated polymorphism in the RT
domain affecting NA resistance data needs further study.
The probability of selecting antiviral resistance is
dependent on the intensity of selection pressure and the
diversity of HBV quasispecies [18]. Among the naive
patients in our study, treatment was not the selection
pressure for developing mutations. Rather, mutations might
have been driven by the patient’s immune system confer-
ring an advantage to the wild-type virus. This is supported
by clustering of mutations in the A–B interdomain,
corresponding to the overlapping ‘a’ determinant of HBsAg,
which is under high host immune pressure; thus this region
is not likely to be important for RT function and antiviral
resistance.
In our study group, putative NAr mutations were
found among the therapy naïve patients too. The therapy
naive patients might have been infected with strains
from other patients who had been treated with NA or
these might be host immune pressure driven mutations.
The dynamics of emerging NA resistance mutations in
untreated patients should be the result of both viral
factors and host factors. However, presence of pretreat-
ment variants in NA-naive patients might also be the re-
sult of transmission of mutant strains from patients or
due to natural variation of HBV. We presume that those
positions in the functional domains or adjacent to the
classical mutation positions might have significance and
needs further consideration (Figure 1).
In India, LMV is widely used and adefovir is an alterna-
tive drug of choice. Therefore, the possibility of detecting
pre-existing HBV variants resistant to these drugs is
more when compared to other drugs introduced rather
recently. In the present study, no established primary
mutations related to antiviral drugs (rtL80I/V-rtI169T-
rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-
rtS202C/G/I-rtM204V/I-rtN236T-rtM250V) were detected
neither among the therapy naïve patients nor among the
non-responders to NA therapy. Although putative
mutations widely found in treatment naive patients
would suggest that they may not be wholly responsible
for non-response to NA therapy; however, this needs
confirmation by in-vitro and follow up studies. As per
the statement of the patients, they have never missed the
drug. However no pill count was done, therefore the ques-
tion of patient’s compliance cannot be ruled out. There-
fore, the role of putative NAr mutations on nonresponse
to antivirals requires further invitro and follow-up studies.
In conclusion, in our study classical antiviral resistance
mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/
V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-rtM204V/I-
rtN236T-rtM250V) were not detected both in naïve
patients and NA therapy non responders infected with
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putative NAr mutations among the study subjects suggest
that they might have role in reduced efficacy of currently
available therapy, but their impact on antiviral efficacy
requires further invitro and follow-up studies. Thus, rou-
tine use of resistance testing in patients before initiating
antiviral therapy is not necessary at present.
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